spacer
home > ebr > summer 2002 > uk multiple sclerosis society
PUBLICATIONS
European Biopharmaceutical Review

UK Multiple Sclerosis Society

The recent controversy in the UK over the cost-effectiveness and availability of beta-interferon (b-IFN) for people with multiple sclerosis (MS) has ignited a huge debate about the way in which health economic data are gathered and used to make health care rationing decisions on a national level. If ever an issue were to require serious attention from researchers and companies developing new biology-based therapeutics, and the patients they aim to treat, this is it. We are at the frontier of a 'new biology-based knowledge' which gives us an understanding of the mechanisms behind the functioning of healthy and diseased cells. Yet if the innovative new biology-based therapeutics we then generate are not deemed 'cost-effective', they may never get to the market and to the patients they are designed to treat (and may not reap the rewards the investors are backing).In this article, we will look at the background and key lessons to be learnt from the review process for b-IFN treatment of MS patients in the UK by talking to two out of three product manufacturers (Serono and Schering), as well as gaining the perspective of the UK Multiple Sclerosis Society.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Glynn McDonald joined the MS Society two years ago from the UK Stroke Association. He has led on all aspects of the campaign to gain access to disease-modifying drugs for people with MS in the UK. Glynn previously worked on a range of policy issues as a career Civil Servant.
Dr Jackie Napier joined Schering Health Care in 1990 and has been Associate Medical Director since 1995. She is responsible for medical support of the secondary care portfolio, including CNS, CVS, oncology, diagnostics and radiopharmaceuticals. For 10 years Jackie has been closely involved with European clinical development and marketing strategy for Betaferon, including the National Institute for Clinical Excellence (NICE) appraisals and appeals, cost-effectiveness modelling and the Department of Health risk-sharing scheme. Last year she contributed to input from the Association of the British Pharmaceutical Industry to the Department of Health's review of NICE.

spacer
Glynn McDonald
spacer
spacer
spacer
Dr Jackie Napier
spacer
spacer
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement